 |
|
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
 |
 |
|
|
|
|
|
|
|
|
|
| 9/2/2010 |
New Study Doesn't Bode Well For Abbott Diet Drug
(Washington, DC) -- A new study funded by Abbott Laboratories is fueling calls for its diet drug Meridia to be taken off the market. The six-year study involved more than ten-thousand overweight or obese patients over age 54 with heart disease, diabetes or both. The high-risk patients who were given Meridia had a 16-percent higher risk of heart attack or stroke compared to those given a placebo. The Meridia patients also had increased blood pressure and heart rates, though there was no increased risk of death. The prescription weight-loss drug has already been banned in Europe. The FDA will hold a public hearing in two weeks to discuss whether similar actions should be taken in the U.S. The study is published in the "New England Journal of Medicine." |
|
|
|
|
|
|
|
|
|
|
|
|
|
|